Sheena Jonathan sold $604K of NTRA (indirect holdings)

Sheena Jonathan sold 1,500 indirectly-held shares of Natera, Inc. (NTRA) at an average of $402.47 ($398.95–$409.36, $0.60M total) across 12 trades on 2026-10-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Oct 21, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, which some traders monitor for signals about future performance.

02

Market read

While the sale is a primary disclosure, its modest size limits broader market relevance.

03

What to watch

Potential upcoming clinical trial milestones or FDA decisions could dominate market reaction, dwarfing the insider sale.

Relevance 4/10Novelty 5/10Timing: post-market on Oct 16

Background

Natera (NTRA) is a genetic testing and diagnostics company. Insider transactions are disclosed via Form 4 filings.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

Director Sheena Jonathan sold $603.7K of Natera shares via a 10b5‑1 plan on Oct 16, reducing her holding to 8,250 shares.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

A $600K sale by a director is material but not large enough to drive a sharp move; investors may view it as a neutral to mildly negative signal.

Market effects

Minimal impact on the broader biotech sector; insider sales are common and rarely shift sector sentiment.

None

None

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals, so price impact may be negligible.

Key entities

  • Sheena Jonathan

    Natera board member executing a pre‑arranged 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.